Literature DB >> 23918000

Demonstrating measurement equivalence of the electronic and paper formats of the Urticaria Patient Daily Diary in patients with chronic idiopathic urticaria.

Emuella M Flood1, James L Zazzali, Jennifer Devlen.   

Abstract

BACKGROUND: The Urticaria Patient Daily Diary (UPDD), originally developed on paper, is a measure of key symptoms of chronic idiopathic urticaria (CIU). The development of the electronic version (eUPDD) involved moderate modifications to the appearance of the paper version.
OBJECTIVE: This study assessed the measurement equivalence of the electronic and paper versions of the UPDD in a sample of patients with CIU.
METHODS: This was a cross-over study of patients with moderate-severe CIU refractory to H1 antihistamines. Patients were randomized to either the eUPDD followed by the paper UPDD or vice versa. The UPDD includes morning and evening questions; both sets were administered together in this study. An hour-long filler task was given between paper and electronic administrations. Patients with stable symptoms between the two assessments were included in the analyses. Cohen's kappa coefficients and intraclass correlation coefficients (ICC) were computed as applicable to assess equivalence.
RESULTS: A total of 91 patients participated (mean age 43 years, 79.1 % female). Symptoms were stable between assessments for 67-74 (74-81 %) patients (varied by symptom). Kappa coefficients ranged from 0.82 to 1.00 for the individual UPDD items. For the Urticaria Activity Score (the sum of the 'itch severity' and 'number of hives' item scores) the ICC was 0.90 for the morning (Wilcoxon p = 0.331) and 0.95 for the evening (Wilcoxon p = 0.836).
CONCLUSIONS: All test-retest statistics in this study were well above the accepted threshold, indicating excellent agreement between the two administration methods. Findings support the measurement equivalence of the electronic and paper versions of the UPDD to measure CIU symptoms.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23918000     DOI: 10.1007/s40271-013-0021-4

Source DB:  PubMed          Journal:  Patient        ISSN: 1178-1653            Impact factor:   3.883


  15 in total

Review 1.  Intraclass correlations: uses in assessing rater reliability.

Authors:  P E Shrout; J L Fleiss
Journal:  Psychol Bull       Date:  1979-03       Impact factor: 17.737

2.  Development of a daily diary for patients with chronic idiopathic urticaria.

Authors:  Susan D Mathias; Stephen C Dreskin; Allen Kaplan; Sarbjit S Saini; Sheldon Spector; Karin E Rosén
Journal:  Ann Allergy Asthma Immunol       Date:  2010-08       Impact factor: 6.347

3.  Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria.

Authors:  Susan D Mathias; Ross D Crosby; James L Zazzali; Marcus Maurer; Sarbjit S Saini
Journal:  Ann Allergy Asthma Immunol       Date:  2011-11-02       Impact factor: 6.347

4.  Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report.

Authors:  Stephen Joel Coons; Chad J Gwaltney; Ron D Hays; J Jason Lundy; Jeff A Sloan; Dennis A Revicki; William R Lenderking; David Cella; Ethan Basch
Journal:  Value Health       Date:  2008-11-11       Impact factor: 5.725

5.  Equivalence of electronic and paper-and-pencil administration of patient-reported outcome measures: a meta-analytic review.

Authors:  Chad J Gwaltney; Alan L Shields; Saul Shiffman
Journal:  Value Health       Date:  2008 Mar-Apr       Impact factor: 5.725

6.  Efficacy of leukotriene receptor antagonist with an anti-H1 receptor antagonist for treatment of chronic idiopathic urticaria.

Authors:  Kong-Sang Wan
Journal:  J Dermatolog Treat       Date:  2009       Impact factor: 3.359

7.  Low-dose and short-term cyclosporine treatment in patients with chronic idiopathic urticaria: a clinical and immunological evaluation.

Authors:  H Serhat Inaloz; Savas Ozturk; Cenk Akcali; Necmettin Kirtak; Mehmet Tarakcioglu
Journal:  J Dermatol       Date:  2008-05       Impact factor: 4.005

8.  How to assess disease activity in patients with chronic urticaria?

Authors:  A Młynek; A Zalewska-Janowska; P Martus; P Staubach; T Zuberbier; M Maurer
Journal:  Allergy       Date:  2008-06       Impact factor: 13.146

9.  Treatment of chronic autoimmune urticaria with omalizumab.

Authors:  Allen P Kaplan; Kusumam Joseph; Robert J Maykut; Gregory P Geba; Robert K Zeldin
Journal:  J Allergy Clin Immunol       Date:  2008-09       Impact factor: 10.793

10.  Leukotriene receptor antagonists in monotherapy or in combination with antihistamines in the treatment of chronic urticaria: a systematic review.

Authors:  Gabriele Di Lorenzo; Alberto D'Alcamo; Manfredi Rizzo; Maria Stefania Leto-Barone; Claudia Lo Bianco; Vito Ditta; Donatella Politi; Francesco Castello; Ilenia Pepe; Gaetana Di Fede; Giovambattista Rini
Journal:  J Asthma Allergy       Date:  2008-12-09
View more
  3 in total

1.  The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU.

Authors:  M Maurer; M Abuzakouk; F Bérard; W Canonica; H Oude Elberink; A Giménez-Arnau; C Grattan; K Hollis; A Knulst; J-P Lacour; C Lynde; A Marsland; D McBride; A Nakonechna; J Ortiz de Frutos; C Proctor; G Sussman; C Sweeney; H Tian; K Weller; D Wolin; M-M Balp
Journal:  Allergy       Date:  2017-07-10       Impact factor: 13.146

2.  Comparison of Urticaria Activity Score Over 7 Days (UAS7) Values Obtained from Once-Daily and Twice-Daily Versions: Results from the ASSURE-CSU Study.

Authors:  Kelly Hollis; Christina Proctor; Doreen McBride; Maria-Magdalena Balp; Lori McLeod; Shannon Hunter; Haijun Tian; Sam Khalil; Marcus Maurer
Journal:  Am J Clin Dermatol       Date:  2018-04       Impact factor: 7.403

3.  Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: Analyses from ASSURE-CSU.

Authors:  G Sussman; M Abuzakouk; F Bérard; W Canonica; H Oude Elberink; A Giménez-Arnau; C Grattan; K Hollis; S Hunter; A Knulst; J-P Lacour; C Lynde; A Marsland; D McBride; M Maurer; A Nakonechna; J Ortiz de Frutos; M Reynolds; C Sweeney; H Tian; K Weller; D Wolin; M-M Balp
Journal:  Allergy       Date:  2018-08       Impact factor: 13.146

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.